INSTITUT UNIVERSITAIRE DU CANCER DE TOULOUSE
Oncopole

ASCO 2021

Communications IUCT-ONCOPOLE (44)

Clinical Science Symposium (2)

- **9012 - METex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib.**

Paul K. Paik, Remi Veillon, Enriqueta Felip, Alexis Cortot, Hiroshi Sakai, Julien Mazieres, Michael Thomas, Niels Reinmuth, Jo Raskin, Pier Franco Conte, Marina Chiara Garassino, Wade Thomas Iams, Frank Griesinger, Dariusz M. Kowalski, Christopher Stroh, Dilafruz Juraeva, Juergen Scheuenpflug, Andreas Johne, Xiuning Le; Memorial Sloan-Kettering Cancer Center, New York, NY; CHU Bordeaux, Service Des Maladies Respiratoires, Bordeaux, France; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Univ. Lille, CHU Lille, Lille, France; Saitama Cancer Center, Saitama, Japan; Centre Hospitalier Universitaire de Toulouse–Hôpital Larrey, Toulouse, France; Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; Asklepios Lung Clinic, Munich-Gauting, Germany; Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital (UZA), Edegem, Belgium; Department of Surgery, Oncology and Gastroenterology, University of Padua, and Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Pius-Hospital, University Medicine Oldenburg, Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Oldenburg, Germany; Department of Lung Cancer and Thoracic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Translational Innovation Platform, Oncology, Merck KGaA, Darmstadt, Germany; Translational Medicine, Department of Bioinformatics, Merck KGaA, Darmstadt, Germany; Clinical Biomarkers and Companion Diagnostics, Merck KGaA, Darmstadt, Germany; Global Clinical Development, Merck KGaA, Darmstadt, Germany; The University of Texas MD Anderson Cancer Center, Houston, TX

https://meetinglibrary.asco.org/record/197686/abstract

- **11510 - Prognosis value of S45F mutation of CTNNB1 in desmoid-type fibromatosis (DF): Prospective analysis of 500 consecutive patients (pts) from ALTITUDES trial.**

Nicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, Sébastien Salas, Francois Le Loarer, Alexandra Meurgey, Sophie Piperno-Neumann, Olivier Collard, Jean Emmanuel Kurtz, Cecile Guillemet, Christine Chevreau, Thomas Ryckewaert, Antoine Italiano, Pascaline Boudou-Rouquette, Daniel Orbach, Axel Le

Cesne, Julien Thery, Marie-Cecile Le Deley, Jean-Yves Blay, Olivier Mir; Department of Medical Oncology, Centre Oscar Lambret and Lille University Hospital, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Oscar Lambret, Lille, France; CEPCM Assistance Publique des Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Medical Oncology, Institut Curie, Paris, France; Institut de Cancérologie Lucien Neuwirth, Saint Etienne, France; Gineco & Institut De Cancérologie Strasbourg Europe, Strasbourg, France; Centre Henri Becquerel, Rouen, France; Institut Claudius Regaud/IUCT-Oncopole, Toulouse, France; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France; Hôpital Cochin, Paris, France; Institut Curie, Paris, France; Gustave Roussy Cancer Institute, Villejuif, France

https://meetinglibrary.asco.org/record/195711/abstract

Oral Abstract Session (3)

- **5500 - Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.**

Isabelle Laure Ray-Coquard, Aude Marie Savoye, Marie-ange Mouret-Reynier, Sylvie Chabaud, Olfa Derbel, Elsa Kalbacher, Marianne Leheurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine, Frank Priou, Nicolas Cloarec, Laurence Venat-Bouvet, Frederic Selle, Dominique Berton, Olivier Collard, Florence Joly, Olivier Tredan; Centre Léon Bérard, University Claude Bernard, Lyon, France; GINECO-Institut Jean Godinot, Reims, France; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France; Departement of Clinical Research,Centre Léon-Bérard, Lyon, France; Institut de Cancérologie, Hôpital Privé Jean Mermoz, Lyon, France; CHU Jean Minjoz, Besançon, France; Centre Henri-Becquerel, Medical Oncology Department, Rouen, France; Institut Claudius Régaud IUCT-O, Toulouse, France; Centre Hospitalier Régional d'Orléans, Orleans, France; Clinique Pasteur, Toulouse, France; Centre Georges-François Leclerc, Dijon, France; CHD Vendee-Hopital Les Oudairies, La Roche-sur-Yon, France; Centre Hospitalier d'Avignon, Avignon, France; GINECO-Centre Hospitalier Universitaire Dupuytren, Limoges, France; Groupe Hospitalier Diaconesses Croix Saint-Simon, and GINECO, Paris, France; GINECO & Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France; Institut de Cancérologie de la Loire, St. Priest En Jarez, France; Department of Medical Oncology, Centre François Baclesse, Caen, France; Departement of Medical Oncology, Centre Léon Bérard, Lyon, France

https://meetinglibrary.asco.org/record/195543/abstract

- **7006 - Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.**

Stéphane De Botton, Karen W. L. Yee, Christian Recher, Andrew Wei, Pau Montesinos, David Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Jordi Esteve, Carolyn Grove, Brian Andrew Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Olga Polyanskaya, Jennifer Sweeney, Hesham Mohamed, Jorge E. Cortes, Pierre Fenaux; Institut Gustave Roussy, Villejuif, France; Princess Margaret Cancer Centre, Toronto, ON, Canada; IUCT-Oncopole, CHU de Toulouse, Toulouse, France; The Alfred Hospital

and Monash University, Melbourne, Australia; Hospital Universitari i Politècnic La Fe, Valencia, Spain; Royal Marsden Hospital, London, United Kingdom; CHU Bordeaux, Université de Bordeaux, Bordeaux, France; Avicenne Hospital Paris XIII University, Bobigny, France; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Hospital Clínic de Barcelona, Barcelona, Spain; PathWest & Sir Charles Gairdner Hospital, Nedlands, Australia; University of California Davis School of Medicine, Sacramento, CA; University College London, London, United Kingdom; Hôpital Saint-Antoine, Université Pierre et Marie Curie, Paris, France; Nantes University Hospital, Nantes, France; Forma Therapeutics, Inc., Watertown, MA; FORMA Therapeutics, Inc., Watertown, MA; Georgia Cancer Center, Augusta, GA; Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France

https://meetinglibrary.asco.org/record/195811/abstract

- **11507 - PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.**

Antoine Italiano, Alban Bessede, Emmanuelle Bompas, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, Francois Bertucci, Maud Toulmonde, Carine A. Bellera, Jean-Philippe Guegan, Catherine Sautes-Fridman, Antoine Bougoüin, Coralie Cantarel, Francois Le Loarer, Jean-Yves Blay, Wolf-Herman Fridman; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France; EXPLICYTE, Bordeaux, France; Institut de Cancérologie de l'Ouest (ICO)-site René Gauducheau, Saint-Herblain, France; Medical Oncology Department, Institut Curie, Paris, France; IUCT-Oncopôle Institut Claudius Regaud, Toulouse, France; Department of Medical Oncology, Centre Oscar Lambret and Lille University Hospital, Lille, France; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France; Institut Bergonié, Department of Medical Oncology, Bordeaux, France; Institut Bergonié, Bordeaux, France; Immusmol, Bordeaux, France; INSERM UMR-S 1138, Cordeliers Research Center, Paris, France; Centre Léon Bérard, Lyon, France

https://meetinglibrary.asco.org/record/195667/abstract

Poster discussion session (8)

- **5513 - Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.**

Felix Blanc-Durand, Elisa Yaniz, Catherine Genestie, Etienne Rouleau, Dominique Berton, Alain Lortholary, Nathalie Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamichhane, Coraline Dubot, Jean-Emannuel Kurtz, Gaetan De Rauglaudre, Nadia Raban, Cyril Abdeddaim, Gwenael Ferron, Marie-Christine Kaminsky, Alba Llop-Guevara, Alexandra Leary; Institut Gustave Roussy, Villejuif, France; Gustave Roussy Cancer Center, Inserm U981, Villejuif, France; Gustave Roussy Cancer Center, INSERM U981, Villejuif, France; Gustave Roussy, Villejuif, France; GINECO & Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France; Institut of Cancerology Catherine de Sienne GINECO-Hôpital Privé du Confluent, Nantes, France; SELARL GOR, Bordeaux, France; Centre Hospitalier Universitaire, Lille, France; ICM Val d'Aurelle, Montpellier, France; Centre Hospitalier Intercommunal de Créteil, Créteil, France; Clinique Tivolis Ducos, Bordeaux, France; GINECO and Institut Curie-Hôpital René Huguenin, Saint-Cloud, France; CHU Stasbourg, Strasbourg, France; GINECO and Institut Sainte-Catherine, Avignon, France; GINECO and CHU La Milétrie, Poitiers, France; Centre de Lutte Contre le Cancer-Centre Oscar Lambret, Lille, France;

GINECO and Institut Claudius Regaud, Toulouse, France; GINECO and Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Gustave Roussy Cancer Center, Villejuif, France

https://meetinglibrary.asco.org/record/196842/abstract

- **7011 - Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.**

Vinod Pullarkat, Keith Pratz, Hartmut Dohner, Christian Recher, Michael J. Thirman, Courtney Denton Dinardo, Pierre Fenaux, Andre C. Schuh, Andrew H. Wei, Arnaud Pigneux, Jun Ho Jang, Gunnar Juliusson, Kazuhito Miyazaki, Dominik Selleslag, Martha Lucia Arellano, Kiran Naqvi, Jun Yu, Jean Ridgeway, Jalaja Potluri, Marina Konopleva; City of Hope Comprehensive Cancer Center, Duarte, CA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Ulm University Hospital, Ulm, Germany; Centre Hospitalier Universitaire de Toulouse, Toulouse, France; The University of Chicago, Chicago, IL; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Paris, France; Princess Margaret Cancer Centre, Toronto, ON, Canada; The Alfred Hospital, Melbourne, Australia; Hôpital Haut Lévêque-CHU de Bordeaux, Bordeaux, France; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Skåne University Hospital, Lund, Sweden; Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan; Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium; Winship Cancer Institute, Atlanta, GA; Genentech, South San Francisco, CA; AbbVie Inc., North Chicago, IL; AbbVie Inc, North Chicago, IL; AbbVie Inc., Chicago, IL

https://meetinglibrary.asco.org/record/195808/abstract

- **7013 - Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.**

Alexander E. Perl, Richard A. Larson, Nikolai Alexandrovich Podoltsev, Stephen Strickland, Eunice S. Wang, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung-Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee-Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramon Velasquez Tiu, Mark J. Levis; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; University of Chicago, Chicago, IL; Yale School of Medicine, New Haven, CT; Vanderbilt Ingram Cancer Center, Nashville, TN; Roswell Park Comprehensive Cancer Institute, Buffalo, NY; David Geffen School of Medicine at UCLA, Los Angeles, CA; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany; Hospital de la Santa Creu I Sant Pau and Josep Carreras Leukemia Research Institute, Barcelona, Spain; University Hospital La Fe, Valencia, Spain; Cancer Research Center of Taulouse, Toulouse, France; Seoul National University Hospital, Seoul, South Korea; University of Fukui, Fukui, Japan; Hokkaido University, Sapporo, Japan; Department of Neuropsychiatry, Asahikawa University School of Medicine, Asahikawa, Japan; Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Astellas Pharma US, Inc., Northbrook, IL; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

https://meetinglibrary.asco.org/record/195805/abstract

- **7018 - Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.**

Keith Pratz, Brian Andrew Jonas, Vinod Pullarkat, Christian Recher, Andre C. Schuh, Michael J. Thirman, Jacqueline Suen Garcia, Courtney Denton Dinardo, Vladimir Vorobyev, Nicola Fracchiolla, Su-Peng Yeh, Jun Ho Jang, Muhit Ozcan, Kazuhito Yamamoto, Arpad Illes, Ying Zhou, Monique Dail, Brenda Chyla, Jalaja Potluri, Hartmut Dohner; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; University of California Davis School of Medicine, Sacramento, CA; City of Hope Comprehensive Cancer Center, Duarte, CA; Centre Hospitalier Universitaire de Toulouse, Toulouse, France; Princess Margaret Cancer Centre, Toronto, ON, Canada; University of Chicago Medical Center, Chicago, IL; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; S. P. Botkin City Clinical Hospital, Moscow, Russian Federation; Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy; China Medical University Hospital, Taichung, Taiwan; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Ankara University School of Medicine Department of Hematology, Ankara, Turkey; Aichi Cancer Center, Nagoya, Japan; University of Debrecen, Medical and Health Science Center, Debrecen, Hungary; AbbVie Inc., North Chicago, IL; Genentech, South San Francisco, CA; AbbVie, Inc., North Chicago, IL; AbbVie Inc., Chicago, IL; Ulm University Hospital, Ulm, Germany

https://meetinglibrary.asco.org/record/195840/abstract

- **8017 - Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).**

Paul G. Richardson, Aurore Perrot, Jesús F. San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey SY. Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Cheng Zheng, Franck Dubin, Helgi Van De Velde, Kenneth Carl Anderson; Dana-Farber Cancer Institute, Boston, MA; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France; Clinical and Translational Medicine, Clínica Universidad de Navarra, Navarra, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain; Ankara University, Ankara, Turkey; 1st Internal Clinic–Clinic of Hematology, General University Hospital, Prague, Czech Republic; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France; Oslo Myeloma Center, Oslo University Hospital, Oslo Norway, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway; University Hospital of Nantes, Nantes, France; Therapeutic Clinic, General Hospital of Athens Alexandra, Athens, Greece; National Taiwan University Hospital, Taipei, Taiwan; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic; Institute of Hematology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, Australia; Sanofi Oncology, Cambridge, MA; Sanofi Oncology Development, Vitry-Sur-Seine, France; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

https://meetinglibrary.asco.org/record/195450/abstract

- **9015 - Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.**

Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Jean-Louis Pujol, Gerard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Celine Mascaux, Denis Moro-Sibilot, François Pinquié, Alexis Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse; Thoracic Oncology Department, CHU Toulouse–Hôpital Larrey, Toulouse, France; Pneumology, Hôpital Cardio-Vasculaire & Pneumologique Louis Pradel, Bron, France; Pneumology, CHU Rennes – Hôpital Pontchaillou, Rennes, France; Multidisciplinary Oncology and Therapeutic Innovations, Hôpital Nord, Marseille, France; Thoracic oncology, Hôpital Arnaud de Villeneuve, Montpellier, France; Department of Thoracic Oncology, CIC INSERM 1425, Université de Paris, Hôpital Bichat, Paris, France; Medical Oncology, CHU De Bordeaux, Hôpital Saint André, Bordeaux, France; Pneumology, CHU Côte de Nacre, Caen, France; Pneumology, Hôpital Laennec - CHU de Nantes, Nantes, France; Pneumology, Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Pneumology, CHU Grenoble, Grenoble, France; Pneumology, Centre Hospitalier du Mans, Le Mans, France; Univ. Lille, CHU Lille, Lille, France; Oncology, Centre Antoine Lacassagne, Nice, France; Pneumology and Thoracic Oncology, Hôpital Tenon, Paris, France; Biostatistics, Intergroupe Francophone de Cancérologie Thoracique, Paris, France; Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris, France; Pneumology, Hopital Jean Minjoz, Besançon, France; Department of Medicine and Thoracic Pathology Committee, Gustave Roussy, Villejuif, France

https://meetinglibrary.asco.org/record/197365/abstract

- **9019 - Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.**

Lisa Derosa, Bertrand Routy, Laurence Zitvogel, Andrew M. Thomas, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Corentin Richard, François Ghiringhelli, Fabrice Barlesi, Arielle Elkrief, Carolina Alves Costa Silva, David Planchard, Nicola Segata, Stéphanie Martinez, Jean-Charles Soria, Benjamin Besse; Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-Sud University, Francepartment of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-Sud University, Villejuif, France; University of Montreal Research Center (CRCHUM), Montreal, QC, Canada; U1015 INSERM, Gustave Roussy Cancer Campus, Paris Saclay University, Villejuif, France; International Research Center, A. C. Camargo Cancer Center, São Paulo, Brazil; Department of Thoracic Oncology, CIC INSERM 1425, Université de Paris, Hôpital Bichat, Paris, France; Hôpital Foch, Suresnes, France; Centre Hospitalier Universitaire de Toulouse–Hôpital Larrey, Toulouse, France; Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France; Pneumology, CHU Grenoble, Grenoble, France; Department of Medical Oncology, CERTIM group, Cochin Port-Royal Hospital, Paris University, AP-HP 5, CARPEM, Paris, France; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Medical Oncology, Center GF Leclerc, Dijon, France; Gustave Roussy Cancer Center, Villejuif, France; University of Montreal Research Center (CRCHUM), Montréal, QC, Canada; Institute Gustave Roussy, Villejuif, France; Gustave Roussy, Department of Medical Oncology, Villejuif, France; Department CIBIO. University of Trento, Trento, Italy; Centre Hospitalier du Pays d'Aix, France, Aix En Provence, France; Gustave Roussy, Villejuif, France; Department of Medicine and Thoracic Pathology Committee, Gustave Roussy, Villejuif, France

https://meetinglibrary.asco.org/record/199385/abstract

Fize.annelaure@iuct-oncopole.fr – Juin 2021

- **9516 - Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.**

Celeste Lebbe, Nicolas Meyer, Laurent Mortier, Ivan Marquez-Rodas, Caroline Robert, Piotr Rutkowski, Marcus O. Butler, Thomas Eigentler, Alexander M. Menzies, Michael Smylie, Ana Maria Arance, Paolo Antonio Ascierto, Inge Marie Svane, Mazhar Ajaz, Nikhil I. Khushalani, Maurice Lobo, Jesus Zoco, Jacopo Pigozzo; APHP Dermatology and CIC, U976, Université de Paris, Hôpital Saint-Louis, Paris, France; Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse, France; Universite Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France; Medical Oncology, General University Hospital Gregorio Marañón & CIBERONC, Madrid, Spain; Gustave Roussy and Université Paris-Saclay, Villejuif-Paris, France; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; University Hospital Tübingen, Tübingen, Germany; Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, NSW, Australia; Medical Oncology and Clinical Research, Cross Cancer Institute, Edmonton, AB, Canada; Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy; Herlev Gentofte Hospital, Herlev, Denmark; Royal Surrey County Hospital, University of Surrey, Guildford, United Kingdom; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, FL; Bristol Myers Squibb, Princeton, NJ; Syneos Health, Braine L'alleud, Belgium; Medical Oncology, IOV - Istituto Oncologico Veneto-IRCCS, Padua, Italy

https://meetinglibrary.asco.org/record/195990/abstract

Poster session (27)

- **1029 - Characterization of long-term responders following treatment with talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 embraca trial.**

Johannes Ettl, Hope S. Rugo, Sara A. Hurvitz, Miguel Martin, Henri Roche, Kyung-Hun Lee, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Carolin Guenzel, Joanne Lorraine Blum, Jennifer Keating Litton; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain; Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France; Seoul National University Hospital, Seoul, South Korea; Medical Oncology Department, Concord Repatriation General Hospital, Concord, Australia; Pfizer Oncology, Milan, Italy; Pfizer Oncology, Berlin, Germany; Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; The University of Texas MD Anderson Cancer Center, Houston, TX

https://meetinglibrary.asco.org/record/198290/abstract

- **1070 - Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.**

François-Clément Bidard, Florence Dalenc, Thibault De La Motte Rouge, Barbara Pistilli, Caroline Cheneau, Catherine Delbaldo, Olfa Derbel, Claire Garnier Tixidre, Nathalie Marques, Sandrine Marques, Lionel Moreau, Frederique Berger, J Lemonnier, Anne-Claire Hardy-Bessard, Suzette Delaloge, Thomas Bachelot; Institut Curie, Paris, France; Institut Claudius Regaud–IUCT Oncopole, Toulouse, France; Centre Eugène Marquis, Rennes, France; Gustave Roussy, Villejuif, France; Centre Hospitalier Bretagne Sud, Lorient, France; Hopital Diaconesses-Croix Saint Simon, Paris, France; Institut de Cancérologie, Hôpital Privé Jean Mermoz, Lyon, France; Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Centre Hospitalier Métropole de Savoie, Chambéry, France; Unicancer, Paris, France; Pôle Santé République, Clermont-Ferrand, France; Biostatistics Unit, INSERM U900, Institut Curie, Paris, France; Medical Oncology Department, CARIO-HPCA and Cooperative Gynecological Cancer Research Group (GINECO), Plerin, France; Centre Léon Bérard, Lyon, France

https://meetinglibrary.asco.org/record/198172/abstract

- **1077 - Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).**

Joyce O'Shaughnessy, Kevin Punie, Mafalda Oliveira, Filipa Lynce, Sara M. Tolaney, Florence Dalenc, Priyanka Sharma, Michaela L. Tsai, Aditya Bardia, Javier Cortes, Michael A. Danso, Stephanie Henry, Alejandra T. Perez, Sara A. Hurvitz, Kevin Kalinsky, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Hope S. Rugo; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Georgetown Lombardi Comprehensive Cancer Center and Medical Oncology, Dana-Farber Cancer Institute, Washington, DC; Dana-Farber Cancer Institute, Boston, MA; Institut Claudius Regaud–IUCT Oncopole, Toulouse, France; University of Kansas Medical Center, Westwood, KS; VPCI Oncology Research, Minneapolis, MN; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; International Breast Cancer Center, Quiron Group, Madrid & Barcelona, Barcelona, Spain; Virginia Oncology Associates, Norfolk, VA; Department of Oncology-Hematology, Radiotherapy, and Nuclear Medicine, CHU UCL Namur, Namur, Belgium; Department of Medicine, University of Miami Miller School of Medicine, Miami, FL; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Winship Cancer Institute, Emory University, Atlanta, GA; Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

https://meetinglibrary.asco.org/record/198258/abstract

- **1080 - Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).**

Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Veronique Dieras, Florence Dalenc, Jennifer Robinson Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O'Shaughnessy, Sibylle Loibl, Luca Gianni, Martine J. Piccart-Gebhart, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Javier Cortes; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Medical Oncology Department and D3i, Institut Curie, Paris, France; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Department of Medical Oncology, Centre Eugene Marquis, Rennes, France; Institut Claudius Regaud–IUCT Oncopole, Toulouse, France; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Medical Oncology Department, Oncologisch Centrum, UZ Brussel, Brussels, Belgium; Miami Cancer Institute, Miami, FL; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Winship Cancer Institute, Emory University, Atlanta, GA; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; Gianni Bonadonna Foundation, Milan, Italy; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium; Department of Clinical Development, Immunomedics, Inc, a subsidiary of Gilead Sciences, Inc., Morris Plains, NJ; International Breast Cancer Center, Quiron Group, Madrid & Barcelona, Barcelona, Spain

https://meetinglibrary.asco.org/record/198275/abstract

- **1090 - Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.**

Jennifer Keating Litton, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri Roche, Kyung-Hun Lee, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Carolin Guenzel, Joanne Lorraine Blum, Hope S. Rugo; The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain; Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France; Seoul National University Hospital, Seoul, South Korea; Medical Oncology Department, Concord Repatriation General Hospital, Concord, Australia; Pfizer Oncology, Milan, Italy; Pfizer Oncology, Berlin, Germany; Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

https://meetinglibrary.asco.org/record/198185/abstract

- **2623 - Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.**

Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki, Iphigenie Korakis, Armelle Vinceneux, Christiane Jungels, Jon Blatchford, Mabrouk M. Elgadi, Nicole Clarke, Claudia Fromond, Nicolas Poirier, Berangere Vasseur, Aurelien Marabelle, Jean-Pierre Delord; Gustave Roussy Cancer Campus, Department of Drug Development (DITEP), Villejuif, France; Centre Léon Bérard, Lyon, France; Institut Jules Bordet, Bruxelles, Belgium; Department of Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Departement of Medical Oncology, Centre Léon Bérard, Lyon, France; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany; Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington, ON, Canada; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany; OSE Immunotherapeutics, Paris, France; OSE Immunotherapeutics, Nantes, France; Institut Claudius Regaud IUCT-Oncopole, Toulouse, France

https://meetinglibrary.asco.org/record/196073/abstract

- **3564 - LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.**

Carlos A. Gomez-Roca, Eduardo Yanez, Seock-Ah Im, Eduardo Castanon Alvarez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Juanita Suzanne Lopez, Bristi Basu, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Hyun Cheol Cheol Chung; Institut Claudius Regaud, Toulouse, France; Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Temuco, Chile; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Clínica Universitaria de Navarra, Pamplona, Spain; Institut de Cancérologie de l'Ouest, Centre René Gauducheau ICO, Saint-Herblain, France; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Department of Medical Oncology (Hospital Clinic)/Translational Genomics and Targeted Therapies in Solid Tumors (IDIBAPs), Barcelona, Spain; The Royal Marsden Foundation Trust and the Institute of Cancer Research, London, United Kingdom; Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Rambam Health Care Campus, Division of Oncology, Haifa, Israel; The Alfred Hospital, Melbourne, VIC, Australia; Merck & Co., Inc., Kenilworth, NJ; Eisai Inc., Woodcliff Lake, NJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

https://meetinglibrary.asco.org/record/196000/abstract

- **4030 - LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.**

Hyun Cheol Cheol Chung, Zarnie Lwin, Carlos A. Gomez-Roca, Federico Longo, Eduardo Yanez, Eduardo Castanon Alvarez, Donna M. Graham, Mark Doherty, Philippe Cassier, Juanita Suzanne Lopez, Bristi Basu, Andrew Eugene Hendifar, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Esma Saada-Bouzid; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia; Institut Claudius

Regaud/IUCT-Oncopole, Toulouse, France; Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain; Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Temuco, Chile; Clínica Universitaria de Navarra, Pamplona, Spain; The Christie NHS Foundation Trust, Manchester, United Kingdom; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Centre Léon Bérard, Lyon, France; The Royal Marsden Foundation Trust and the Institute of Cancer Research, London, United Kingdom; Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA; Rambam Health Care Campus, Division of Oncology, Haifa, Israel; The Alfred Hospital, Melbourne, VIC, Australia; Merck & Co., Inc., Kenilworth, NJ; Eisai Inc., Woodcliff Lake, NJ; Centre de Lutte Contre le Cancer Antoine Lacassagne, Nice, France

https://meetinglibrary.asco.org/record/199037/abstract

- **4080 - Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.**

Luis Villanueva, Zarnie Lwin, Hyun Cheol Cheol Chung, Carlos A. Gomez-Roca, Federico Longo, Eduardo Yanez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Andrew Eugene Hendifar, Corinne Maurice-Dror, Sanjeev Singh Gill, Tae Won Kim, Daniel Heudobler, Nicolas Penel, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Donna M. Graham; Fundación Arturo López Pérez, Providencia, Santiago, Chile; Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Institut Claudius Regaud, Toulouse, France; Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain; Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Temuco, Chile; Institut de Cancérologie de l'Ouest, Centre René Gauducheau ICO, Saint-Herblain, France; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Department of Medical Oncology (Hospital Clinic)/Translational Genomics and Targeted Therapies in Solid Tumors (IDIBAPs), Barcelona, Spain; Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA; Rambam Health Care Campus, Division of Oncology, Haifa, Israel; The Alfred Hospital, Melbourne, VIC, Australia; Asan Medical Center, Seoul, South Korea; University Hospital Regensburg, Regensburg, Germany; Centre Oscar Lambret, Lille, France; Merck & Co., Inc., Kenilworth, NJ; Eisai Inc., Woodcliff Lake, NJ; The Christie NHS Foundation Trust, Manchester, United Kingdom

https://meetinglibrary.asco.org/record/198732/abstract

- **4096 - Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.**

Sophie Cousin, Carine A. Bellera, Jean Philippe Guégan, Thibault Mazard, Carlos A. Gomez-Roca, Jean Philippe Metges, Coralie Cantarel, Antoine Adenis, Iphigenie Korakis, Pierre-guillaume Poureau, Mariella spalato-Ceruso, Kevin Bourcier, Michèle Kind, Isabelle Soubeyran, Alban Bessede, Antoine Italiano; Medical Oncology, Institute Bergonié, Bordeaux, France; Institut Bergonié, Bordeaux, France; Immusmol, Bordeaux, France; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Universitaire du Cancer de Toulouse (IUCT), Toulouse, France; Institut de Cancerologie et d'Hematologie, CHU Morvan Pole Régional de Cancerologie, Brest, France; IRCM, Inserm, Université Montpellier, ICM, Montpellier, France; Department of Oncology, Institut Claudius Regaud, IUCT-

Oncopole, Toulouse, France; Institut de Cancérologie, Brest, France; Institut Bergonié, Department of Imaging, Bordeaux, France; Molecular Pathology Unit-Department of Biopathology, Institut Bergonié, Bordeaux, France; EXPLICYTE, Bordeaux, France; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France

https://meetinglibrary.asco.org/record/198923/abstract

- **4116 - Efficacy and safety of 177Lu‑DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): Data from the NETTER-R international, retrospective registry.**

Dominique Clement, Shaunak Navalkissoor, Rajaventhan Srirajaskanthan, Frédéric Courbon, Lawrence Dierickx, Amy Eccles, Valerie Lewington, Mercedes Mitjavila, Juan Carlos Percovich, Benoît Lequoy, Beilei He, Ilya Folitar, John Ramage; King's College Hospital, London, United Kingdom; Royal Free Hospital, London, United Kingdom; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France; Guy's and St. Thomas' Hospitals, London, United Kingdom; Guy's Hospital, London, United Kingdom; Hospital Universitario Puerta de Hierro, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Advanced Accelerator Applications, A Novartis Company, Geneva, Switzerland

https://meetinglibrary.asco.org/record/199045/abstract

- **4556 - Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).**

Jose Luis Perez-Gracia, Aaron Richard Hansen, Rikke Helene Loevendahl Eefsen, Carlos A. Gomez-Roca, Sylvie Negrier, Paolo Pedrazzoli, Jae-Lyun Lee, Teresa Alonso Gordoa, Cristina Suarez Rodriguez, Begona Mellado, Victor Moreno, Alejo Rodriguez-Vida, Arif Hussain, Nicole Getzmann, David Dejardin, Christophe Boetsch, Anton Kraxner, Taner Vardar, Volker Teichgräber, Thomas Powles; Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Herlev Hospital, Herlev, Denmark; Institut Claudius Regaud/IUCT-Oncopole, Toulouse, France; Departement of Medical Oncology, Centre Léon Bérard, Lyon, France; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea; Hospital Universitario Ramón y Cajal, Madrid, Spain; Medical Oncology, Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus, Barcelona, Spain; Hospital Clínic, Provincial de Barcelona, Barcelona, Spain; START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain; Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain; University of Maryland Cancer Center, Baltimore, MD; Roche, Basel, Switzerland; Roche, Biostatistics Oncology pRED, Basel, Switzerland; Roche Innovation Center, Basel, Switzerland; Roche/Genentech, Basel, Switzerland; F. Hoffmann-La Roche AG, Basel, Switzerland; Hoffmann-La Roche, Basel, Switzerland; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

https://meetinglibrary.asco.org/record/197682/abstract

- **7039 - Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib**

Michael W Deininger, Tim H. Brümmendorf, Dragana Milojkovic, Francisco Cervantes, Françoise Huguet, Andrea Viqueira, Eric Leip, Simon Purcell, Jorge E. Cortes; University of Utah Health Care, Salt Lake City, UT; Universitätsklinikum RWTH Aachen, Aachen, Germany; Hammersmith Hospital, Imperial College, London, United Kingdom; Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; Institut Universitaire du Cancer, Toulouse, France; Pfizer SLU, Madrid, Spain; Pfizer Inc, Cambridge, MA; Pfizer Ltd, London, United Kingdom; Georgia Cancer Center, Augusta, GA

https://meetinglibrary.asco.org/record/196280/abstract

- **7543 - CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.**

Catherine Thieblemont, Bettina Altmann, Olivier Casasnovas, Fabian Frontzek, Franck Morschhauser, Lucie Oberic, Viola Poeschel, Olivier Fitoussi, Loïc Renaud, Georg Lenz, Nicolas Mounier, Andreas Rosenwald, German Ott, Thierry Molina, Marie Parrens, Loic Chartier, Marita Ziepert, Herve Tilly, Norbert Schmitz; AP-HP at Saint-Louis Hospital, Hemato-oncology, Paris University, Paris, France; Institute for Medical Informatics, Statistics and Epidemology, Leipzig University, Leipzig, Germany; CHU Dijon, Dijon, France; University Hospital of Muenster, Department of Internal Medicine, Muenster, Germany; Hôpital Claude Huriez, Lille, France; Instiut Universitaire Du Cancer, Toulouse, France; Department Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany; Polyclinique de Bordeaux nord Aquitaine, Bordeaux, France; CHRU Lille, Lille, France; University Hospital Münster, Münster, Germany; Department of Hematology, CHU l'Archet, Nice, France; Institut für Pathologie, Universität Würzburg, Würzburg, Germany; Insitute of Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany; APHP, Paris, France; Centre Hospitalier Universitaire, Bordeaux, Bordeaux, France; LYSARC, Pierre-Bénite, France; Department of Hematology, Centre Henri Becquerel, University of Rouen, Rouen, France

https://meetinglibrary.asco.org/record/198961/abstract

- **7544 - Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.**

Charles Herbaux, Herve Ghesquieres, Reda Bouabdallah, Stephanie Guidez, Emmanuel Gyan, Remi Gressin, Nadine Morineau, Loic Ysebaert, Steven Le Gouill, Camille Laurent, Herve Tilly, Roch Houot, Gandhi Damaj, David Sibon, Pierre Feugier, Catherine Thieblemont, Corinne Haioun, Karine Tarte, Franck Morschhauser, Guillaume Cartron; Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille, France; Centre Leon Berard, Lyon, France; Institut Paoli-Calmettes, Marseille, France; Poitiers University Hospital/INSERM CIC 1402, Poitiers, France; Tours University Hospital and CNRS ERL7001 LNOX, EA7501, Tours, France; Université Grenoble Alpes, Institut Albert Bonniot, Departement d'Hématologie Clinique, Centre Hospitalier et Universitaire de Grenoble-Alpes, Grenoble, France; CHD Vendée, Hematology, La Roche-sur-Yon, France; Department of Haematology, Institut Universitaire du Cancer de Toulouse— Oncopôle, Toulouse, France; CHU Nantes and UMR892 INSERM, Nantes, France; IUCT Oncopole, Toulouse, France; Department of Hematology, Centre Henri Becquerel, University of Rouen, Rouen, France; Centre Hospitalier Universitaire Pontchaillou, Rennes, France; Department of Hematology, University Hospital, School of Medicine, Caen, France; Hôpital

Necker-Enfants Malades Hematology, Paris, France; CHU Brabois Service d'Hématologie et Médecine Interne, Vandoeuvre Les Nancy, France; AP-HP at Saint-Louis Hospital, Hemato-oncology, Paris University, Paris, France; Hopital Henri Mondor, AP-HP, Créteil, France; CHU Rennes, Rennes, France; CHU Lille-Hopital Claude Huriez, Lille, France; CHU de Montpellier, Montpellier, France

https://meetinglibrary.asco.org/record/197508/abstract

- **8041 - LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.**

Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, Aurore Perrot, Niels W.C.J. van de Donk, Hartmut Goldschmidt, Martin F. Kaiser, Ravi Vij, Francesca Gay, Annemiek Broijl, Anna Potamianou, Caline Sakabedoyan, Vadim Strulev, Jordan Mark Schecter, Martin Vogel, Tonia Nesheiwat, Robert Wapenaar, Michel Delforge, Hermann Einsele, Philippe Moreau, on behalf of the MMY4001 Clinical Study; Hospital Clinico Universitario de Salamanca, Salamanca, Spain; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Amsterdam University Medical Center, VU University Medical Center, Amsterdam, Netherlands; University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany; Institute of Cancer Research, London, United Kingdom; Washington University School of Medicine, St. Louis, MO; Division of Hematology, University of Torino, Torino, Italy; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Janssen-Cilag, Neuss, Germany; EMEA Medical Affairs, Janssen-Cilag, Beirut, Lebanon; EMEA Medical Affairs, Janssen Pharmaceutica NV, Beerse, Belgium; Janssen R&D, Raritan, NJ; Janssen Global Services, LLC, Raritan, NJ; Medical Affairs, Legend Biotech USA Inc, Piscataway, NJ; Janssen-Cilag BV, Breda, Netherlands; Department of Hematology, University Hospitals (UZ) Leuven, Leuven, Belgium; Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany; Hematology, University Hospital Hotel-Dieu, Nantes, France

https://meetinglibrary.asco.org/record/195439/abstract

- **8526 - Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.**

Damien Vasseur, Cécile Jovelet, Nathalie Cozic, Julien Mazieres, Fabrice Barlesi, Jaafar Bennouna, Radj Gervais, Lionel Moreau, Henri Berard, Olivier Molinier, Denis Moro-Sibilot, Pierre Jean Souquet, Elodie Amour, Franck Morin, Gerard Zalcman, Jean-Charles Soria, Virginie Westeel, Ludovic Lacroix, Benjamin Besse; Gustave Roussy, Villejuif, France; Biostatistics Unit, Gustave Roussy Cancer Campus, Villejuif, France; Centre Hospitalier Universitaire de Toulouse–Hôpital Larrey, Toulouse, France; Aix-Marseille University, CEPCM CLIP, Assistance Publique Hôpitaux de Marseille, Marseille, France; University Hospital of Nantes, Digestive Oncology, Nantes, France; Centre François Baclesse, Caen, France; Centre Hospitalier Pneumologie Colmar, Colmar, France; Hopital D'instruction Des Armes Sainte-Anne, Toulon, France; Le Mans Regional Hospital, Le Mans, France; Unité d'Oncologie Thoracique, Service Hospitalier Universitaire Pneumologie Physiologie Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France; University Hospital of Lyon-Sud, Lyon, France; IFCT, Paris, France; Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris, France; Department of Thoracic

Oncology, CIC INSERM 1425, Université de Paris, Hôpital Bichat, Paris, France; Gustave Roussy Cancer Campus, Department of Drug Development (DITEP), Villejuif, France; Pneumology, Hopital Jean Minjoz, Besançon, France; Cancer Genetics Laboratory, Departement of Pathology and Medical Biology, Gustave Roussy, Villejuif, France; Department of Medicine and Thoracic Pathology Committee, Gustave Roussy, Villejuif, France

https://meetinglibrary.asco.org/record/198772/abstract

- **9062 - EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.**

Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Perol, Nicolas Girard, Eric Dansin, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Coureche Kaderbhai, Pascale Dubray-Longeras, Sandrine Hiret, Eric Pichon, Christelle Anne Clement-Duchene, Anne-Laure Martin, Gaetane Simon, Xavier Quantin; Pneumology, Centre Hospitalier Intercommunal (CHI) Creteil, Créteil, France; Department of Biostatistics, Institut Claudius Regaud-IUCT, Toulouse, France; Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France; Centre Léon Bérard, Department of Medical Oncology, Lyon, France; Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; Department of Medical Oncology, Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Medical Oncology, Institute Bergonié, Bordeaux, France; Oncology, Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France; Gustave Roussy, Department of Medical Oncology, Villejuif, France; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Centre Georges-François Leclerc, Dijon, France; Centre Jean Perrin, Medical Oncology Department, Clermont-Ferrand, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre Hospitalier Universitaire, Tours, France; Institut de Cancérologie de Lorraine, Nancy, France; Unicancer, Paris, France; Institut Régional du Cancer, Montpellier, France

https://meetinglibrary.asco.org/record/200675/abstract

- **9084 - Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.**

Jyoti D. Patel, Xiuning Le, Remi Veillon, Ian Churchill Anderson, Christine M. Bestvina, Ingel Demedts, Marina Chiara Garassino, Julien Mazieres, Masahiro Morise, Egbert F. Smit, S. Peter Eggleton, Aurora OBrate, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Paul K. Paik; Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, IL; The University of Texas MD Anderson Cancer Center, Houston, TX; CHU Bordeaux, Service Des Maladies Respiratoires, Bordeaux, France; St. Joseph Heritage Healthcare, Santa Rosa, CA; University of Chicago Medical Center, Chicago, IL; AZ Delta, Roeselare, Belgium; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Centre Hospitalier Universitaire de Toulouse–Hôpital Larrey, Toulouse, France; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Global Clinical Development, Merck KGaA, Darmstadt, Germany; Global Medical Affairs, Merck KGaA, Darmstadt, Germany; Department of Biostatistics, Merck KGaA, Darmstadt, Germany; Memorial Sloan-Kettering Cancer Center, New York, NY

https://meetinglibrary.asco.org/record/200644/abstract

Fize.annelaure@iuct-oncopole.fr – Juin 2021

- **9089 - Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.**

Giuseppe Curigliano, Justin F. Gainor, Frank Griesinger, Michael Thomas, Vivek Subbiah, Christina S Baik, Daniel Shao-Weng Tan, Dae Ho Lee, Daniel Misch, Elena Garralda, Dong-Wan Kim, Luis G. Paz-Ares, Julien Mazieres, Stephen V. Liu, Gregory Peter Kalemkerian, Yariv Houvras, Daniel W. Bowles, Aaron Scott Mansfield, Alena Zalutskaya, Anthonie J. van der Wekken; European Institute of Oncology, IRCCS and University of Milano, Milan, Italy; Massachusetts General Hospital, Boston, MA; Pius-Hospital, University of Oldenburg, Oldenburg, Germany; Thoracic Oncology, Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; University of Texas MD Anderson Cancer Center, Houston, TX; University of Washington School of Medicine, Seattle, WA; National Cancer Centre Singapore, Singapore, Singapore; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Helios Clinic Emil von Behring, Berlin, Germany; Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain; Seoul National University Hospital, Seoul, South Korea; Hospital Universitario 12 de Octubre, Madrid, Spain; Institut Universitaire du Cancer, Toulouse, France; Georgetown University, Department of Hematology and Oncology, School of Medicine, Washington, DC; University of Michigan, Ann Arbor, MI; Weill Cornell Medical College, New York, NY; University of Colorado School of Medicine, Aurora, CO; Mayo Clinic, Rochester, MN; Blueprint Medicines Corporation, Cambridge, MA; University of Groningen and University Medical Centre Groningen, Groningen, Netherlands

https://meetinglibrary.asco.org/record/200463/abstract

- **9095 - Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301- SAFIR02-LUNG intergroup trial.**

Benjamin Besse, Maryam Karimi, Pascale Tomasini, Henri Janicot, Judith Raimbourg, Clarisse Audigier-Valette, Anne Madroszyk, Francois Chomy, Eric Dansin, Julien Mazieres, Alexis Cortot, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Jean-Charles Soria, Fabrice Barlesi; Department of Medicine and Thoracic Pathology Committee, Gustave Roussy, Villejuif, France; Department of Biostatistics, Gustave Roussy; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Aix-Marseille Université, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France; Department of Medical Oncology, Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied, Clermont Ferrand, France; Department of Medical Oncology, ICO- Centre René Gauducheau, Nantes, France; Department of Medical Oncology, CHI de Toulon - Hôpital Sainte-Musse, Toulon, France; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Department of Medical Oncology, Institut Bergonié, Bordeaux, France; Department of Medical Oncology, Centre Oscar Lambret, Lille, France; Centre Hospitalier Universitaire de Toulouse–Hôpital Larrey, Toulouse, France; Univ. Lille, CHU Lille, Lille, France; Department of Genetics, Institut Curie and University of Paris, Paris, France; Cancer Genetics Laboratory, Departement of Pathology and Medical Biology, Gustave Roussy, Villejuif, France; Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France; Molecular Pathology Unit-Department of Biopathology, Institut Bergonié, Bordeaux, France; Department of Innate Immunity and Immunotherapy, ICO- Centre Paul Papin, Angers, France; Inserm UMR981 and

Department of Medical Oncology, Gustave Roussy Cancer, Campus and Université Paris Saclay, Villejuif, France; Unicancer, Paris, France; Gustave Roussy Cancer Campus, Department of Drug Development (DITEP), Villejuif, France; Department of Medical Oncology, Gustave Roussy; Department of Medical Oncology, AP-HM - Hôpital Nord, Marseille, Villejuif and Marseille, France

https://meetinglibrary.asco.org/record/200589/abstract

- **9546 - KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).**

Åse Bratland, Eva Muñoz-Couselo, Laurent Mortier, Osama Roshdy, Rene Gonzalez, Jacob Schachter, Ana Maria Arance, Florent Grange, Nicolas Meyer, Abhishek Jagdish Joshi, Salem Billan, Brett Gordon Maxwell Hughes, Jean-Jacques Grob, Karthik Ramakrishnan, Eric (Pingye) Zhang, Burak Gumuscu, Ramona F. Swaby, Ralf Gutzmer; Oslo University Hospital, Oslo, Norway; Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universite Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France; McGill University, Montreal, QC, Canada; Centro Estatal de Cancerologiade Chihuahua, Chihuahua, Mexico; Sheba Medical Center at Tel-Hashomer, Ramat Gan, Israel; Hospital Clínic de Barcelona, Barcelona, Spain; CHU Reims–Hôpital Robert Debre, Reims, France; Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse, France; Townsville Cancer Centre, Townsville, QLD, Australia; Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel; Royal Brisbane and Women's Hospital, Herston, and University of Queensland, Brisbane, QLD, Australia; Aix-Marseille University, Marseille, France; Merck & Co., Inc., Kenilworth, NJ; Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany

https://meetinglibrary.asco.org/record/197035/abstract

- **9561 - Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.**

Hussein Abdul-Hassan Tawbi, Georgina V. Long, Nicolas Meyer, Boris Breznen, Charmy Vyas, Lisa Leung, Andriy Moshyk, Divya Pushkarna, Pratik K. Thakkar, Mir Sohail Fazeli, SRIVIDYA KOTAPATI, Dirk Schadendorf; The University of Texas MD Anderson Cancer Center, Houston, TX; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia; Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse, France; Evidinno Outcomes Research Inc., Vancouver, BC, Canada; Bristol Myers Squibb, Princeton, NJ; Bristol Myers Squibb, Uxbridge, United Kingdom; Department of Dermatology, University of Essen; German Cancer Consortium (DKTK), Partner Site Essen, Essen, Germany

https://meetinglibrary.asco.org/record/197162/abstract

- **11544 - Long-term evaluation of the novel radioenhancer NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma treated in the phase II/III Act.In.Sarc trial.**

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat, Sebastien Carrère, Anne Ducassou, Sunyach Marie, Peter Agoston, Angela M. Hong, Augustin Mervoyer, Marco Rastrelli, Cecile Le Pechoux, Victor

Moreno, Rubi Khaw Li, Béatrice Tiangco, Zsuzsanna Papai, Act.In.Sarc. investigators; Institut Gustave Roussy, Villejuif, France; Maria Sklodowska-Curie Institute-Oncology Center, Institute of Oncology, Warsaw, Poland; Centre François Baclesse, Caen, France; Montpellier Cancer Institute, Montpellier, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berad, Lyon, France; Országos Onkológiai Intézet, Budapest, Hungary; Chris O'Brien Lifehouse, Camperdown, Australia; Institut de Cancérologie de l'Ouest - René Gauducheau, Radiation Therapy Department, Saint-Herblain, France; Istituto Oncologico Veneto IRCCS, Padova, Italy; Gustave Roussy Cancer Campus, Villejuif, France; Hospital Fundación Jiménez Díaz, Madrid, Spain; St Luke's Medical Center, Quezon City, Philippines; The Medical City Cancer Center, Pasay City, Philippines; State Health Center, Hungarian Defense Forces, Oncology Department, Budapest, Hungary

https://meetinglibrary.asco.org/record/198133/abstract

- **TPS2066 - BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).**

Nuria Kotecki, Maria Alice B Franzoi, Marianne Paesmans, Florian Clatot, Edith Borcoman, Anthony Goncalves, Philippe Barthelemy, Claire Cheymol, Jean-Pierre Delord, Andrea Gombos, Vincent Vanhaudenarde, Stephane Holbrechts, Francois P. Duhoux, Jean-Luc Re Canon, Lore Decoster, Hannelore denys, Caroline Duhem, Nadège Kindt, Ahmad Awada; Institut Jules Bordet, Bruxelles, Belgium; Oncology Department, Institut Jules Bordet, and Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Data Centre, Institut Jules Bordet - Université Libre de Bruxelles (ULB), Brussels, Belgium; INSERM U1245, IRON Group, Centre Henri Becquerel, University Hospital, University of Normandy, Rouen, France; Institut Curie, Paris, France; Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; Hopital Civil-CHRU Strasbourg, Strasbourg, France; Centre Oscar Lambret, Lille, France; Department of Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Institut Jules Bordet, Brussels - Belgium, Belgium; Clinique et Maternité Sainte-Elisabeth, Namur, Belgium; CHU Ambroise Paré, Mons, Belgium; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium; Department of Oncology-Hematology, Grand Hôpital de Charleroi, Charleroi, Belgium; University Hospital, Brussels, Belgium; BGOG and Ghent University Hospital, Ghent, Belgium; Centre Hospitalier, Luxembourg, Luxembourg; Institut Jules Bordet - Université Libre de Bruxelles, Bruxelles, Belgium; Department of Oncology Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

https://meetinglibrary.asco.org/record/201160/abstract

- **TPS3620 - Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).**

Kanwal Pratap Singh Raghav, Takayuki Yoshino, Rosine Guimbaud, Ian Chau, Marc Van Den Eynde, Joan Maurel, Jeanne Tie, Tae Won Kim, Kun-Huei Yeh, Daniel Barrios, Kojiro Kobayashi, Emarjola Bako, Mehreteab Aregay, Gerold Meinhardt, Salvatore Siena; The University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Japan; CHU Toulouse, Toulouse, France; The Royal Marsden Hospital NHS Foundation Trust, London and Sutton, United Kingdom; Cliniques Universitaires St-Luc, Brussels, Belgium; Hospital Clinic Barcelona, Barcelona, Spain; Peter

MacCallum Cancer Centre, Melbourne, Australia; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; National Taiwan University Hospital, Taipei, Taiwan; Daiichi Sankyo, Basking Ridge, NJ; Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano, Milan, Italy

https://meetinglibrary.asco.org/record/201238/abstract

- **TPS4588 - Consolidative radiotherapy for metastatic urothelial bladder cancer patients without progression and with no more than three residual metastatic lesions following first line systemic therapy: A prospective randomized comparative phase II trial (BLAD RAD01/GETUG-AFU V07).**

Jonathan Khalifa, Damien Pouessel, Mathieu Roumiguie, Paul Sargos, Genevieve Loos, Ulrike Schick, Naji Salem, Nathalie Mesgouez-Nebout, Yohann Loriot, Christophe Hennequin, Emmanuel Meyer, Pierre Blanchard, Valentine Guimas, Laurent Votron, Pierre Graff-Cailleaud, Gilles Crehange, Muriel Mounier, Angélique Massoubre, Leonor Chaltiel, Thomas Filleron; Institut Claudius Regaud/IUCT-Oncopole, Toulouse, France; Institut Claudius Regaud/IUCT-Oncopole, CHU Rangueil, Toulouse, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Cancérologie et d'Hématologie CHRU de Brest, Brest, France; Department of Radiotherapy, Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest-site Paul Papin, Angers, France; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Hopital Saint-Louis, Paris, France; Department of Radiation Oncology, Centre François Baclesse, Caen, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France; Clinique Claude Bernard, Albi, France; Institut Curie, Paris, France

https://meetinglibrary.asco.org/record/201227/abstract

- **TPS5604 - ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy.**

Isabelle Laure Ray-Coquard, Alexandra Leary, Frédéric Bigot, Laure Montane, Michel Fabbro, Anne-Claire Hardy-Bessard, Frederic Selle, Camille Chakiba, Alain Lortholary, Dominique Berton, Valérie Chevalier-Evain, Magali Provansal, Laurence Gladieff, Marie-Christine Kaminsky, Sandro Pignata, Elena Ioana Braicu, Christophe Caux, Marc-Henri Stern, Audrey Bellesoeur, Elsa Kalbacher; Centre Léon Bérard and University Claude Bernard Lyon 1 and GINECO, Lyon, France; Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, France; Institut de Cancerologie de l'Ouest, ANGERS, France; Centre Léon-Bérard, Lyon, France; ICM Val d'Aurelle, Montpellier, France; Medical Oncology Department, CARIO-HPCA and Cooperative Gynecological Cancer Research Group (GINECO), Plerin, France; Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France; Institut Bergonié, Bordeaux, France; Institut of Cancerology Catherine de Sienne GINECO-Hôpital Privé du Confluent, Nantes, France; GINECO & Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France; Centre Oscar Lambret, Lille, France; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France; Institut Claudius Regaud, IUCT-Oncopole and GINECO, Toulouse, France; GINECO and Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France; Istituto Nazionale Tumori IRCCS-Fondazione

G. Pascale, Naples, Italy; Department of Gynecology, Charité Medical University, Berlin, Germany; Centre Leon Berard, Lyon, France; Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, France

https://meetinglibrary.asco.org/record/201278/abstract

- **TPS11576 - REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).**

Florence Duffaud, Sylvie Chabaud, Julien Gautier, Celine Ferlay, Séraphine Vizoso, Mehdi Brahmi, Sarah Benezech, Armelle Dufresne, Perrine Marec-Berard, Isabelle Laure Ray-Coquard, Elsa Kalbacher, Olivier Collard, Nicolas Penel, Maria Rios, Emmanuelle Bompas, Christine Chevreau, Olivier Mir, Pascaline Boudou-Rouquette, Jean-Yves Blay, Sophie Piperno-Neumann, French Sarcoma Group; La Timone University Hospital, Marseille, France; Departement of Clinical Research,Centre Léon-Bérard, Lyon, France; Centre Léon Bérard, Lyon, France; Centre Léon-Bérard, Lyon, France; Centre Léon Bérard, Institut d'Hématologie et Oncologie Pédiatrique, Lyon, France; Institut d'Hematologie et d'Oncologie Pédiatrique, Lyon, France; Centre Léon Bérard, University Claude Bernard, Lyon, France; CHU Besançon, Besançon, France; Institut de Cancérologie de la Loire, St. Priest En Jarez, France; Department of Medical Oncology, Centre Oscar Lambret and Lille University Hospital, Lille, France; Centre Alexis Vautrin, Nancy, France; Institut de Cancérologie de l'Ou, Nantes, France; IUCT-Oncopôle Institut Claudius Regaud, Toulouse, France; Gustave Roussy Cancer Institute, Villejuif, France; Hôpital Cochin, Paris, France; Medical Oncology, Institut Curie, Paris, France

https://meetinglibrary.asco.org/record/201365/abstract

Session : Publication Only (4)

- **e18542 - Are neglected breast cancer relates to lifestyle and socioeconomic environment?**

Anne-lise Farcy, Lacaze Jean Louis, Charlotte Vaysse, Cyrille Delpierre, Gabrielle Selmes, Mony Ung, Clemence BRAC de la PERRIERE, Carole Domenech, Eleonora De Maio, Bastien Cabarrou, Florence Tremollieres, Florence Dalenc; Centre Hospitalo-Universitaire (CHU) De Toulouse, Institut Universitaire Du Cancer De Toulouse-Oncopole (IUCT-O), Université De Toulouse (UPS) Service De Gynécologie, Toulouse, France; Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département d'Oncologie médicale, Toulouse, France; Centre Hospitalo-Universitaire (CHU) de Toulouse, Institut Claudius Regaud (ICR) Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse (UPS), Département de Chirurgie Oncologique, Toulouse, France; Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O),Université de Toulouse (UPS), INSERM unité 1027, Toulouse, France; Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de Chirurgie Oncologique, Toulouse, France; Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de radiologie, Toulouse, France; Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Toulouse, France; Centre Hospitalo-Universitaire (CHU) de Toulouse, Hôpital Paule de Viguier, INSERM U1048-I2MC, Equipe 9, Centre de Ménopause, Toulouse, France; Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Centre de Recherches en

Cancérologie de Toulouse (CRCT), Université de Toulouse, UPS, INSERM, Département d'Oncologie médicale, Toulouse, France

https://meetinglibrary.asco.org/record/199337/abstract

- **e16512 - The importance of evaluating long term responder fraction using complementary statistical approaches in immune checkpoint inhibitors phase III trials: An in-silico study using keynote 045 study.**

Fanny Mathevet, Damien Pouessel, Jean-Yves Dauxois, Nadine Houede, Christine Chevreau, Raphaël Porcher, Stephane Culine, Jean-Pierre Delord, Thomas Filleron; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Department of Medical Oncology, Institut Claudius Régaud-IUCT-Oncopole, Toulouse, France; Institut de Mathématiques de Toulouse, UMR5219, Université de Toulouse, CNRS, INSA, F-31077, Toulouse, France; Montpellier University, Département d'oncologie Médicale, CHU Caremeau,, Nîmes, France; Institut Claudius Regaud/IUCT-Oncopole, Toulouse, France; Université Paris Descartes, Paris, France; Department of Medical Oncology, Hospital Saint-Louis, Paris, France

https://meetinglibrary.asco.org/record/198040/abstract

- **e16566 - Prognosis impact of serous metastases (SMs) in clear cell renal cell carcinoma patients in the GETUG-AFU-26 NIVOREN phase II trial.**

Florian Bardet, Cécile Dalban, Christine Chevreau, Sylvie Negrier, Brigitte Laguerre, Gwenaelle Gravis, Marine Gross-Goupil, Stephane Oudard, Philippe Barthélémy, Jean Marc Ferrero, Antoine Thiery-Vuillemin, Hakim Mahammedi, Berangere Narciso, Lionnel Geoffrois, Florence Tantot, Bernard Escudier, Sylvain Ladoire, Laurence Albiges; Universitary Hospital, Dijon, France; Centre Léon Bérard, Lyon, France; IUCT-Oncopôle Institut Claudius Regaud, Toulouse, France; Departement of Medical Oncology, Centre Léon Bérard, Lyon, France; Centre Eugéne Marquis, Rennes, France; Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France; Bergonie Institute, Cancer Center, Bordeaux, France; Department of Medical Oncology, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France; Institut de Cancérologie Strasbourg Europe, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; University Hospital Jean Minjoz, Besançon, France; Comprehensive Cancer Center, Clermont Ferrand, France; Universitary Hospital, Tours, France; Centre Alexis Vautrin, Vandoeuvre-Lès-Nancy, France; UNICANCER, Le Kremlin-Bicêtre, France; Gustave Roussy, Villejuif, France; Georges-François Leclerc Cancer Center, Dijon, France; Department of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Sud, Boston, MA

https://meetinglibrary.asco.org/record/197985/abstract

- **e23537 - Impact of surgical margins on survival in cutaneous sarcomas: A nationwide study of French Sarcoma Group (FSG) from NETSARC Database.**

Mélanie Saint-Jean, Audrey Michot, Andrea Cavalcanti, Gauthier Decanter, Thomas Meresse, Celeste Lebbe, Frédéric Marchal, Sebastien Carrère, Florence Duffaud, Sophie Piperno-Neumann, Angélique Brunot, Louis-Romée Le Nail, Justine Gantzer, Damien Giacchero, Sylvain Causeret, Pascale Dubray-Longeras, Francois Bertucci, Loic Campion, Armelle Dufresne, Emmanuelle Bompas; Medical Oncology

Department, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Medical Oncology Department, Institut Bergonié, Bordeaux, France; Surgery Department, Gustave Roussy Cancer Campus, Villejuif, France; Surgical Oncology Department, Centre Oscar Lambret, Lille, France; Surgical Oncology Department, IUCT Oncopole, Toulouse, France; Université de Paris, INSERM U976 and CIC, AP-HP, Saint Louis Hospital, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France; Montpellier Cancer Institute, Montpellier, France; Medical Oncology, La Timone hospital, Marseille, France; Institut Curie, Paris, France; Medical Oncology, Centre Eugène Marquis, Rennes, France; Department of Orthopedic Surgery, CHRU de Tours and UMR1238 INSERM Université de Nantes, Sarcomes Osseux et Remodelage des Tissus Calcifiés, Faculté de Médecine, Tours, France; Medical Oncology Department, ICANS, Strasbourg, France; Onco-Dermatologie, Centre Antoine Lacassagne, Nice, France; Surgery Department, Centre Georges François Leclerc, Dijon, France; Centre Jean Perrin, Medical Oncology Department, Clermont-Ferrand, France; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre Léon-Bérard, Lyon, France

https://meetinglibrary.asco.org/record/198530/abstract

Fize.annelaure@iuct-oncopole.fr – Juin 2021